Hemophilia has six main treatment options: factor replacement, medications that control bleeding, inhibitor treatments, factor-mimicking medications, rebalancing agents, and gene therapy. Some options prevent bleeds, while others help stop bleeding after it starts.
Hemophilia A involves factor VIII (8), while hemophilia B involves factor IX (9). Other bleeding disorders can involve platelets, von Willebrand factor, or other parts of blood clotting. Without treatment, serious bleeding can harm joints and organs.
In the United States, hemophilia treatment centers bring together specialists who help people plan their care and find support. Here’s what to know about your treatment options.
Factor replacement gives the body the clotting factor it needs through an intravenous (IV) infusion. They work by replacing the missing clotting factor in the blood. There are two types: standard half-life therapies and extended half-life therapies.
How often someone receives factor therapy depends on their condition and treatment plan. Factor therapy may be used in three main ways:
Some factor replacement therapies are approved by the U.S. Food and Drug Administration (FDA) for all three uses, while others are only approved for one or two.
Recombinant products are lab-made clotting factors. A majority of people with hemophilia use them to help their blood clot.
Brands of recombinant factor VIII concentrates to treat hemophilia A include:
Brands of recombinant factor IX concentrates for hemophilia B include:
Brands of recombinant factor concentrates for rare bleeding disorders include:
Factor replacement concentrates are made from donated human plasma. The plasma is checked for diseases and heated to kill any germs. Alphanate, Humate-P, and Wilate are used to treat hemophilia A and von Willebrand disease.
Profilnine (factor IX complex containing factors II [2], VII, IX and X [10]) and Coagadex (factor X) are examples of other factor replacement concentrates made from human plasma.
Factor I (1) deficiency can be treated with fibrinogen concentrates such as Fibryga and RiaSTAP. Cryoprecipitate (“cryo”) — a product made from frozen blood plasma — is mainly a backup for urgent, serious bleeding when fibrinogen concentrate isn’t available.
There are fewer products available to treat rare bleeding disorders. These include deficiencies in clotting factors I, II, and V (5), as well as those caused by deficiencies in multiple factors.
Rare bleeding disorders may be treated with fresh frozen plasma or prothrombin complex concentrate, both of which contain a combination of clotting factors. Fresh frozen plasma is often needed in large quantities to be effective.
Cryoprecipitate, as mentioned earlier, may also be used, but unlike the other two multifactor products mentioned, cryoprecipitate does not undergo treatment to kill viruses.
Among the treatments listed above, recombinant clotting factors are typically the most expensive. However, they are also considered the safest option because they are made without human plasma, which eliminates the risk of bloodborne infections.
Nonfactor replacement therapies are hemophilia treatments that support clotting or prevent bleeding in other ways.
Antifibrinolytics are drugs that prevent bleeding by preventing the breakdown of clots. These medications may be recommended to improve healing or help with excessive menstrual bleeding.
Aminocaproic acid comes in oral and IV forms. Cyklokapron is IV tranexamic acid. Oral tranexamic acid is also available.
Desmopressin is a human-made version of the hormone vasopressin. It can be used to treat mild hemophilia A and some types of von Willebrand disease, depending on the person’s response.
Desmopressin is believed to work by increasing the levels of von Willebrand factor and factor VIII in the blood. Desmopressin is available as an injection (sold as DDAVP).
Stimate (desmopressin acetate) nasal spray was recalled in 2020. The FDA approved its return in 2026, and U.S. availability was planned to start in October 2026. Check with a pharmacy for current stock. Stimate shouldn’t be used for type 2B von Willebrand disease.
Hormonal contraceptives, such as the birth control pill or intrauterine devices (IUDs), can help control excessive menstrual bleeding in some individuals with bleeding disorders.
In some people, bleeding disorders are related to vitamin K deficiency. This can lead to a deficiency of multiple clotting factors, such as factors II, VII, IX, and X. Vitamin K may be taken orally or injected.
People with inhibitors can use bypassing agents, immune tolerance treatment, or certain nonfactor medications.
Inhibitors are antibodies (immune proteins) that attack and destroy replacement clotting factors. The body creates inhibitors when the immune system recognizes infused factor treatments as foreign substances and starts to destroy them.
Inhibitors can block factor replacement, but newer nonfactor medications can still help prevent bleeds. About 30 percent of people with severe hemophilia A develop inhibitors. It’s less common for people with hemophilia B to develop inhibitors — about 5 percent — but inhibitors can be harder to treat in those with hemophilia B.
Treatment for people with inhibitors can be complicated. Sometimes, a higher dose of a clotting factor may help. If it doesn’t, other treatments are available.
Bypassing agents help to form a clot without the need for factor VIII or factor IX.
Activated prothrombin complex concentrate (Feiba) contains a combination of clotting factors to help treat and prevent bleeds. NovoSeven RT and Sevenfact are recombinant factor VIIa concentrates approved to treat people with hemophilia A and hemophilia B with inhibitors.
Inhibitors themselves can be treated in some people via immune tolerance induction (ITI). ITI involves taking large, regular doses of replacement factor for months or years. The goal of this treatment is to “train” the immune system to stop making inhibitors.
ITI is successful in 70 percent to 80 percent of people with hemophilia A. However, this treatment requires a large time and money commitment.
These medications copy some of the work of clotting factor VIII to help prevent bleeding in hemophilia A.
Biologics are special treatments made from living sources, like cells or proteins. Emicizumab-kxwh (Hemlibra) is a biologic drug made of a monoclonal antibody (laboratory-made immune protein). It can be used to treat hemophilia A in people with and without inhibitors.
Emicizumab-kxwh is believed to work by activating the coagulation process by connecting factors IXa (9a) and X. Since emicizumab-kxwh isn’t a clotting factor, it can help prevent bleeding even in people with inhibitors.
This medication is given as a subcutaneous (under the skin) injection.
Rebalancing agents are a type of nonfactor therapy used to treat hemophilia A and B with and without inhibitors. They work by restoring the balance between factors that help the blood clot and factors that prevent the blood from clotting.
Concizumab-mtci (Alhemo) and marstacimab-hncq (Hympavzi) help blood clot better by blocking a protein called tissue factor pathway inhibitor, which normally slows down clotting. Fitusiran (Qfitlia) works by blocking antithrombin, a protein that usually slows clotting. This helps the blood clot better.
These medications are injected under the skin. Concizumab-mtci, fitusiran, and marstacimab-hncq have different approved uses and age limits. Fitusiran can prevent bleeding in people ages 12 and older with hemophilia A or B, with or without inhibitors.
These medications may raise the risk of dangerous blood clots, so careful dosing and monitoring matter.
Gene therapy can help some adults with hemophilia A or B, even though the availability of specific treatments has changed.
Gene therapy is a treatment that provides a working copy of the defective gene causing hemophilia. With a working copy of the gene, a person with hemophilia may be able to make the missing clotting factor on their own.
Etranacogene dezaparvovec-drlb (Hemgenix) is a one-time IV gene therapy for certain adults with hemophilia B. Doctors check whether a person is eligible and monitor them after treatment. Valoctocogene roxaparvovec-rvox is no longer commercially available in the U.S.
Wash a small cut, press firmly with clean gauze, and cover it. If bleeding won’t stop, call the person’s care team.
Get emergency help for heavy bleeding or a head injury. Follow the person’s emergency treatment plan.
Mild hemophilia may need treatment mainly after injuries or before surgery. Moderate or severe hemophilia often calls for regular treatment to prevent bleeding.
Having an emergency kit on hand can be helpful. Treatment also depends on a person’s bleeding history, joint health, and whether they have inhibitors.
Get updates directly to your inbox.
Become a member to get even more
This is a member-feature!
Sign up for free to view article comments.
We can now add Gene therapy to the list of treatments for Hemophilia B....Thanks CSL Behring... I will be closely following their clinical progression. As a severe Hemophilia A patient I can't wait… read more
We'd love to hear from you! Please share your name and email to post and read comments.
You'll also get the latest articles directly to your inbox.